Pharma Journalist -

Magnet Biomedicine, a leading biopharmaceutical company advancing molecular glue discovery with rational selection and design, announced a collaboration and license agreement with Eli…
Read More...

Sobi announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Gamifant (emapalumab-Izsg) for use in adult and…
Read More...

Medigene AG and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and develop off-the-shelf T cell…
Read More...

Regeneron Pharmaceuticals, Inc. announced that the  U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for…
Read More...

Eli Lilly and Company announced at a press conference in Washington, D.C., plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical…
Read More...

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult…
Read More...

RedHill Biopharma Ltd. announced that it has entered into an exclusive worldwide development and commercialization licensing agreement, excluding North America (the "Agreement"), with…
Read More...

Summit Therapeutics Inc. announced a clinical trial collaboration with Pfizer Inc. to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with…
Read More...

Mirum Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved CTEXLI (chenodiol) tablets, a bile acid, for the treatment of adults with…
Read More...

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) for Opdivo (nivolumab) plus Yervoy …
Read More...